Headlands Technologies LLC Acquires 3,387 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Headlands Technologies LLC raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 222.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,909 shares of the medical research company's stock after buying an additional 3,387 shares during the period. Headlands Technologies LLC's holdings in Thermo Fisher Scientific were worth $2,554,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Legacy Investment Solutions LLC purchased a new stake in shares of Thermo Fisher Scientific in the third quarter valued at $26,000. Barrett & Company Inc. purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $28,000. FPC Investment Advisory Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $28,000. Pillar Financial Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $29,000. Finally, Missouri Trust & Investment Co acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at approximately $29,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO traded down $19.18 on Thursday, hitting $469.88. 2,812,372 shares of the stock traded hands, compared to its average volume of 1,631,024. The business has a fifty day moving average price of $536.85 and a two-hundred day moving average price of $549.69. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 52 week low of $468.39 and a 52 week high of $627.88. The firm has a market capitalization of $177.27 billion, a PE ratio of 28.43, a P/E/G ratio of 2.99 and a beta of 0.79.

Remove Ads

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be issued a $0.43 dividend. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.37%. Thermo Fisher Scientific's dividend payout ratio is presently 10.41%.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the sale, the executive vice president now directly owns 16,363 shares of the company's stock, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at $59,506,950.58. This represents a 7.99 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,900 shares of company stock valued at $13,106,062. Corporate insiders own 0.34% of the company's stock.

Analyst Upgrades and Downgrades

TMO has been the subject of several recent research reports. StockNews.com upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, January 14th. Scotiabank increased their price objective on Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a report on Monday, February 3rd. Royal Bank of Canada set a $693.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 31st. UBS Group raised their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a report on Friday, January 31st. Finally, Citigroup decreased their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average price target of $653.23.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.